|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Conversion From Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-Month Results of the CRAF Study显示文摘 | Fuad S. Shihab Thomas H. Waid David J. Conti Harold Yang Michael J. Holman Laura C. Mulloy Alice K. Henning John Holman M Roy First | 2008 | Transplantation2008，，9： | 1 |
| 2 | Safety of full dose intravenous rt-PA followed by intra-arterial therapy for acute cerebral infarction显示文摘 | Raul G Shihab Masrur Leonardo M | 2010 | Neurology2010，74，： | 1 |
| 3 | Modeling and simu- lation of solar absorption system Performance in bei- rut显示文摘 | Ghaddar N K Shihab M Bdeir F | 1997 | Renewable Energy1997，10，4： | 1 |
| 4 | Sodium depletionenhances fibrosis and the expression of TGF - betal and ma- trix proteins in experimental chronic cyclosporine nephropa- thy 显示文摘 | Shihab F S Andoh T F Tanner A M | 1997 | Am J Kidney Dis1997，30，1： | 1 |
| 5 | Role of transforming growth factor- beta 1 in experimental chronic cyclosporine nephropathy显示文摘 | Shihab F S Andoh T F Tanner A M Noble N A Border W A Franceschini N | 1996 | Kidney Int1996，49，： | 1 |
| 6 | Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis显示文摘 | Shihab F S Andoh T F Tanner A M Yi H Bennett W M | 1999 | Kidney Int1999，56，： | 1 |
| 7 | Angiotensin II blockade decreases TGF-betaland matrix proteins in cyclosporine nephropathy显示文摘 | Shihab F S Bennett W M Tanner A M | 1997 | Kidney Int1997，52，3： | 1 |
| 8 | Expression ofapoptosis regulatory genes in chronic cyclosporine nephrotoxicity fa-vors apoptosis显示文摘 | SHIHAB F S ANDOH T F TANNER A M | 1999 | Kidney Int1999，56，6： | 1 |
| 9 | Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy显示文摘 | Shihab F S Andoh T F Tanner A M | 1996 | Kidney Int1996，49，4： | 1 |
| 10 | Ex- pression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis显示文摘 | Shihab F S Andoh T F Tanner A M | 1999 | Kidney International1999，56，6： | 1 |
| 11 | Variation of biological half-life of methylmercury in man显示文摘 | Al-Shahristani H Shihab K M | 1974 | Archives Environmental Health1974，28，： | 1 |
| 12 | Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity显示文摘 | SHIHAB F S BENNETT W M YI H | 2005 | Transplantation2005，79，4： | 1 |
| 13 | Response to an- tiretroviral therapy in HIV-infeeted patients attending a public, urban clinic in Kampala, Uganda显示文摘 | Spacek LA H M Shihab MR Kamya | 2006 | Clin Infect Dis2006，42，25： | 1 |
| 14 | Angiotensin Ⅱ blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy显示文摘 | Shihab F S Bennett W M Tanner A M | | 0，，： | 1 |
| 15 | Donor precondi- tioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation 显示文摘 | Fuad S Shihab William M Bennett Takeshi F Andoh | 2009 | Transplantation2009，87，3： | 1 |
| 16 | Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and metaanalysis of randomized trials显示文摘AIM: To systematically assess risk of pancreatic adverse events with glucagon-like peptide-1(GLP-1) receptor agonist and dipeptidyl peptidase-4(DPP-4) inhibitor drugs.METHODS: We searched Pub Med, Embase, CINAHL, Cochrane review of clinical trials, pharmaceutical company clinical trials register, United States Food and Drug Administration website, European Medicines Agency website and Clinical Trials.gov for randomized controlled trials from inception to October 2013. Randomized control trial studies were selected for inclusion if they reported on pancreatic complication events and/or changes in pancreatic enzyme levels(serum amylase and serum lipase) as adverse events or as serious adverse events for patients who were on GLP-1 receptor agonist and DPP-4 inhibitor drugs. Two independent reviewers extracted data directly. We performed Peto odds ratio(OR) fixed effect meta-analysis of pancreatic adverse events a, and assessed heterogeneity with the I^2 statistic.RESULTS: Sixty-eight randomized controlled trials were eligible. A total of 60720 patients were included in our analysis of the association of risk of pancreatic complication events with GLP-1 agents. A total of 89 pancreatic related adverse events occurred among the GLP-1 agents compared to 74 events among the controls. There was a statistically significant increased risk of elevation of pancreatic enzymes associated with GLP-1 agents compared with control(Peto OR = 3.15, 95%CI: 1.56-6.39, P = 0.001, I2 = 0%). There was no statistically significant difference in the risk of pancreatic adverse event associated with GLP-1 agent compared with controls(Peto OR = 1.00, 95%CI: 0.73-1.37, P = 1.00, I2 = 0%). There were a total of 71 pancreatitis events in patients on GLP-1 agents and 56 pancreatitis events occurred in the control patients. There were 36 reports of pancreatic cancer in these studies. Of these cases, 2 used linagliptin, 2 used alogliptin, 1 used vildagliptin, 7 used saxagliptin while 6 used sitagliptin. The remaining 18 cases occurred among controls.CONCLUSION: Although GLP-1 based agents are associated with pancreatic enzyme elevation, we were unable to confirm a significant risk of pancreatitis or pancreatic cancer. | Hasan M Shihab Tokunbo Akande Kacie Armstrong Sonal Singh Yoon K Loke | 2015 | World Journal of Meta-Analysis2015，3，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员